CMS aiming for more transparency in drug pricing negotiations

MT HANNACH
1 Min Read
Disclosure: This website may contain affiliate links, which means I may earn a commission if you click on the link and make a purchase. I only recommend products or services that I personally use and believe will add value to my readers. Your support is appreciated!

January 29, 2025 2:30 p.m.Pfizer Inc. (PFE)CMS,, Amgn,, GSK,, Bmy,, Mrk,, Teva,, AZN,, BHC,, Alpmf,, Irwd,, AbbvBy: Val Brickates Kennedy,, Editor -in -chief of his news
Medicare, national health insurance program in the United States.

Olivier Le Moal

The US Centers for Medicare & Medicaid Services, or CMS, said that it was considering means to bring “greater transparency” to the pricing for medication negotiation program mandated under the law on the reduction of the Inflation of 2022.

In a statement published on Wednesday, CMS said

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *